Advani, A. S., Tse, W., Jia, X., Elson, P., Cooper, B., Ali-Osman, F., … Sekeres, M. A. (2015). Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML). In BLOOD (Vol. 126). Orlando, FL: AMER SOC HEMATOLOGY.

Advani, Anjali S., William Tse, Xuefei Jia, Paul Elson, Brenda Cooper, Francis Ali-Osman, Jino Park, et al. “Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML).” In BLOOD, Vol. 126. AMER SOC HEMATOLOGY, 2015.

Advani AS, Tse W, Jia X, Elson P, Cooper B, Ali-Osman F, et al. Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML). In: BLOOD. AMER SOC HEMATOLOGY; 2015.

Advani, Anjali S., et al. “Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML).” BLOOD, vol. 126, no. 23, AMER SOC HEMATOLOGY, 2015.

Advani AS, Tse W, Jia X, Elson P, Cooper B, Ali-Osman F, Park J, Rao AV, Rizzieri DA, Wang ES, Cotta CV, Kalaycio M, Sobecks RM, Rouphail B, Maciejewski JP, Fensterl J, Bailey L, Carew JS, Foster B, Rush ML, Adams D, Griffiths EA, Sekeres MA. Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML). BLOOD. AMER SOC HEMATOLOGY; 2015.